HOUSTON, March 9, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on
behalf of the MD Anderson Cancer Center ("MD Anderson"), today
announced that it has entered into a Manufacturing Services
Agreement with Sanmina Corporation, a leading integrated
manufacturing solutions provider, as it transitions to
manufacturing for the limited launch of its Rapid Acoustic Pulse
("RAP") device for tattoo removal expected in mid-2020.
Under the terms of the agreement, which is effective
March 6, 2020, Sanmina Corporation
will manufacture Soliton's RAP device and replaceable cartridges.
"We are delighted to continue to partner with Sanmina
Corporation as we begin our transition into the manufacturing phase
of commercialization ahead of the planned mid-2020 limited launch
of our unique RAP device," said Dr. Chris
Capelli, Soliton's President, CEO and co-founder. "Sanmina's
expertise and world-class service are a great match for Soliton's
innovative device, which is FDA-cleared for tattoo removal and we
believe has potential in additional aesthetic indications including
cellulite removal and fibrotic scarring, and we look forward to
working with them in the years ahead."
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in clinical and preclinical testing, including the
potential to improve the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth and the potential to treat keloid and hypertrophic
scars by targeting the stiffened environment in the intracellular
matrix.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability to partner with
Sanmina in manufacturing the RAP device and to launch its product
in mid-2020, and the potential additional capabilities of the RAP
technology in other indications. These statements relate to
future events, future expectations, plans and prospects. Although
Soliton believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Soliton has attempted to identify forward-looking statements by
terminology including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under in our SEC filings, including under the heading "Item 1A.
Risk Factors" in the Form 10-K for year ended December 31, 2019 we filed with the SEC and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-signs-agreement-with-global-manufacturer-sanmina-301019433.html
SOURCE Soliton, Inc.